CHP2

Across TCGA pan-cancer cohorts, CHP2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CHP2 data layer compared with 17 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CHP2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CHP2 expression acts as an unfavorable survival marker, although some lineages such as GBM and UCEC show a favorable association.

LUAD, OV, and ESCA are the cancer types where CHP2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.158	0.835	<.001	24	view →
OV	OS	Median	II,III,IV	0.308	0.691	.033	18	view →
ESCA	OS	Median	All	0.272	0.704	.018	6	view →
GBM	DFS	Median	All	1.000	0.245	.016	4	view →
UCEC	DFS	Median	All	1.000	0.635	.032	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CHP2–LUAD (OS)

Open the LUAD breakdown →